Pfizer vaccines stimulate a strong immune response in babies over 6 months old

Pfizer’s vaccine proved effective in children aged 6 months to 5 years after 3 doses reuters

AFP news agency on May 23 quoted the announcement of Pfizer/BioNTech said the vaccine produced by this joint venture proved to be safe and effective for children aged 6 months to 5 years when it received 3 doses.

The information is given in the context of the US Food and Drug Administration (FDA).FDA) plan to meet to review vaccine certification Covid-19 for this age group, which is not eligible for vaccination in most of the above countries world should worry many parents.

Pfizer/BioNTech evaluated 3 doses at a dose of 3 micrograms/nose in clinical trials and the results showed that the vaccine stimulated a strong immune response. Side effects were similar in the vaccine and placebo groups.

According to initial estimates, the effectiveness of the vaccine is 80.3%. “We are very pleased that our formula for the youngest children, which has been carefully selected with 1/10 of an adult dose, has resulted in a strong immune response,” said CEO Albert Bourla of Pfizer.

“We hope to soon complete the submission of documents to authorities around the world to bring this vaccine to children as soon as possible”, according to Mr. Bourla.

The FDA plans to allow three days in June for experts to meet and possibly decide on the certification of this Covid-19 vaccine for children under 5 years old and Moderna’s vaccine for children under 6 years old. Moderna’s vaccine has 2 doses with a dose of 25 micrograms / nose.

Initially, the FDA was expected to evaluate Pfizer’s vaccine with two doses in February, but data shows that this dose does not stimulate an adequate immune response in children 2 to 4 years of age. The FDA then recommended viewing data for the 3-dose dose.

According to new data, 1,678 children received 3 doses of Pfizer’s vaccines at least 2 months after the 2nd dose, at Omicron is the dominant variant. The analysis showed that antibody levels were similar to those in the 16-25 year old group receiving 2 full doses. No adverse reactions were observed in the trial, with the majority of adverse events being mild or moderate.